Please login to the form below

Not currently logged in

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

Merck/MSD’s Keytruda has demonstrated positive results in combination with chemotherapy in locally advanced or first-line metastatic oesophageal cancer.

The phase 3 KEYNOTE-590 trial evaluated Keytruda (pembrolizumab) in combination with chemotherapy in first-line oesophageal cancer.

The PD-L1 inhibitor met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the study, and improved outcomes compared to the current standard of care.

The study also met the key secondary endpoint of objective response rate, with signifiant improvements for the Keytruda combination compared to chemotherapy alone.

“Oesophageal cancer is a devastating malignancy with a high mortality rate and few treatment options in the first-line setting beyond chemotherapy,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

“In this pivotal study, Keytruda plus chemotherapy resulted in superior overall survival compared with the current standard of care in the full study population and across all patient groups evaluated. These results build upon our research reinforcing the survival benefits of Keytruda, and we look forward to engaging regulatory authorities as quickly as possible,” he added.

Currently, Bristol Myers Squibb’s rival checkpoint inhibitor Opdivo (nivolumab) is Keytruda’s only potential competitor in oesophageal cancer. The drug scored US Food and Drug Administration back in June for the treatment of second-line unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma that has progressed after chemotherapy treatment.

In the phase 3 ATTRACTION-3 trial, which evaluated Opdivo in this patient population, the PD-1 inhibitor met the primary endpoint of OS, demonstrating a 23% reduction in the risk of death and a 2.5 month improvement in OS when compared to chemotherapy alone. The survival benefit with Opdivo treatment was observed regardless of PD-L1 expression levels.

Keytruda is also already approved as a mono therapy for the second-line treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, but only for patients whose tumours express PD-L1.

According to Merck, the full detailed results from the KEYNOTE-590 trial will be shared with global regulatory authorities and will also be present at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Article by
Lucy Parsons

21st August 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...